Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · Document series

Draft structure of the document registry

Consultation on the structure of the document registry: the identifier scheme, the fields carried for every document, and the way a superseded document is represented. The draft assigns a permanent identifier at first publication and never reassigns it.

Document identifier
CEI-CP-028
Series
Public comment period
Version
1.0
Published
10 Jan 2025
Last reviewed
10 Jan 2025
Next review
10 Jan 2026
Identifier
10.71829/cei.cp.28
Certainty
Not rated
Cycle
2024 Q4
Window
21 Oct 2024 – 20 Dec 2024
Status
Closed
Submissions
9

§1Consultation and window

§1.1Window

Opened
21 October 2024
Closed
20 December 2024
Duration
60 days
Status
Closed — the disposition is published
Document under consultation
Document series
Submissions received
9

§1.2Consultation questions

The secretariat put the following questions. A submission was not required to address them and several did not; the questions record what the Institute was uncertain about rather than restricting what a respondent could raise.

  1. Is the identifier scheme robust to a document changing series or type after publication?
  2. Should the registry record the review date and the next review date for every document, including those with no scheduled review?
  3. Is the representation of a withdrawn document sufficient for a reader who arrives at it from an external link?

§1.3How a submission is handled

  • Every submission is signed. The Institute publishes no anonymous submission.
  • Every submission carries a declared interest. A declaration of no interest is itself a declaration and is recorded as one. A declaration is not a disqualification and the Institute has never given a submission less weight on that ground.
  • A submission from an employee of a marketing-authorisation holder is identified as an industry submission on its face, following a unanimous consultation on the conflicts policy.
  • Every submission receives a secretariat response and a disposition. Submissions that are not accepted remain published in full; the Institute does not remove a submission because it disagrees with it.
  • There is no voting, no reputation score, no reply thread and no editing after receipt.

§1.4Outcome

The registry structure was ratified with amendments. A withdrawn document now carries the reason for withdrawal and a link to whatever supersedes it, and the next-review field is recorded as not scheduled rather than left blank.

The disposition table, listing each submission with its disposition and the resulting amendment, is at §3.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.